Browse by Medical Category
The mission of our clinical research is to foster discoveries in the novel therapies of inflammatory bowel diseases, gastrointestinal and pancreatic cancer, hepatitis, and other gastrointestinal disorders. Our doctors are committed to providing the best care and management of diseases while testing cutting-edge therapies.
Back to full list of clinical trials
Ongoing clinical trials for pancreatic cancer: Actively recruiting
Family History of Pancreatic Cancer
Management and Follow-up of High-Risk Individuals and Families with Hereditary Pancreatic Cancer
To create a database of subjects and families with a hereditary pattern of pancreatic cancer in order to measure outcomes among those who undergo radiologic and endoscopic screening.
Basic eligibility criteria:
Individuals with a family history of at least two first degree relatives with primary site pancreatic cancer; individuals with a family history of at least three relatives with primary site pancreatic cancer independent of degree; individuals with two relatives with primary site pancreatic cancer, one being a first degree relative and the second being a first degree relative of the former; individuals with BRCA2 or FAMM/p16 gene mutations with at least one relative with primary site pancreatic cancer independent of degree; individuals with Peutz-Jeghers Syndrome; individuals with Hereditary Pancreatitis.
Daniel C. Chung, MD
Lara Novak; 617-726-0161
Pancreatic cystic lesions
Optimization of storage and shipment conditions for pancreatic cystic fluid specimens
This study will help us to determine the optimal preservative solution for shipment and storage of the pancreatic cyst fluids. Leftover pancreatic cystic fluid will be collected and stored. Three different preservative solutions will be compared to the snap-frozen technique.
Patients undergoing an endoscopic fine needle aspiration for pancreatic cystic lesion, over the age of 18. Leftover cystic fluid will be studied in four different storage and shipment conditions.
William Brugge, MD
Ebubekir S. Daglilar, MD, CRC; 6617-724-0462
EUS-Guided Injection of Albumin-bound Paclitaxel into Pancreatic Cysts: A Pilot Study
The goal of the study is to determine the safety of injection of albumin-bound paclitaxel into pancreatic cysts to treat pancreatic cystic lesions that are not eligible for surgical resection.
Abdominal CT imaging within 6 months with diagnosed pancreatic cystic lesion, over the age of 18.
Establishment of Database of Patients with Pancreatic Cystic Lesions Who Underwent Endoscopic Ultrasound-guided Fine Needle Aspiration
The goal of this study is to create a database of subjects with a pancreatic cystic lesion in order to measure outcomes among those who undergo radiologic and endoscopic fine needle aspiration.
Patients undergoing an endoscopic fine needle aspiration for pancreatic cystic lesion
Differentiation between low- and high-risk pancreatic cystic lesions with optical coherence tomography imaging
The goal of this study is to develop an imaging probe and image processing methods for pancreatic cystic lesions. This new imaging method will provide equivalent or superior diagnostic information relative to visual inspection of endosonography. The specific aim of this study is to determine the accuracy of OCT imaging for differentiation between low and high risk pancreatic cystic lesions. Patients who undergo endoscopic ultrasound imaging for evaluation of pancreatic cystic lesions will undergo optical coherence tomography imaging in the same session.
Patients who will undergo endoscopic ultrasound imaging for evaluation of pancreatic cystic lesion
Cholangiocarcinoma, pancreatic cancer
Endoscopic Radiofrequency Ablation of Malignant Bile Duct Strictures: A pilot study
This is a prospective pilot study of endoscopic ablation of a malignant bile duct stricture with ERCP guided radiofrequency ablation. Patients undergo one treatment during ERCP and resume their standard medical or surgical care after the procedure.
Patients must have evidence of biliary obstruction by imaging and laboratory testing, as well as evidence of malignancy.
Ebubekir Daglilar, MD, CRC; 617-724-0462
Back to Top